New transcatheter valve safe, effective for treating aortic regurgitation

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial’s prespecified goal of 25% to show non-inferiority, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Stem cell infusion timing can prevent acute graft-versus-host disease

A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), highlighting the role of the recipient’s circadian rhythms. The team was led by Prof. Zhan Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences and Chief Physician Zhu Xiaoyu from the Department of Hematology at the First Affiliated Hospital of the University of Science and Technology of China.

Low-dose apixaban comparable to full dose for preventing venous thromboembolism recurrence in patients with cancer

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period. These findings from the API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).